Enantioselective Total Synthesis of Hyperforin by Sparling, Brian Andrew et al.
 
Enantioselective Total Synthesis of Hyperforin
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Sparling, Brian A., David C. Moebius, and Matthew D. Shair.
2013. Enantioselective Total Synthesis of Hyperforin. Journal of
the American Chemical Society 135, no. 2: 644–647.
Published Version doi:10.1021/ja312150d
Accessed February 19, 2015 5:11:54 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12563735
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Open Access Policy Articles, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#OAPSubscriber access provided by HARVARD UNIV
Journal of the American Chemical Society is published by the American Chemical
Society. 1155 Sixteenth Street N.W., Washington, DC 20036
Published by American Chemical Society. Copyright © American Chemical Society.
However, no copyright claim is made to original U.S. Government works, or works
produced by employees of any Commonwealth realm Crown government in the course
of their duties.
Communication
Enantioselective Total Synthesis of Hyperforin
Brian Andrew Sparling, David C. Moebius, and Matthew D. Shair
J. Am. Chem. Soc., Just Accepted Manuscript • DOI: 10.1021/ja312150d • Publication Date (Web): 28 Dec 2012
Downloaded from http://pubs.acs.org on December 28, 2012
Just Accepted
“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted
online prior to technical editing, formatting for publication and author proofing. The American Chemical
Society  provides  “Just  Accepted”  as  a  free  service  to  the  research  community  to  expedite  the
dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts
appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been
fully peer reviewed, but should not be considered the official version of record. They are accessible to all
readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered
to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published
in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just
Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor
changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers
and  ethical  guidelines  that  apply  to  the  journal  pertain.  ACS  cannot  be  held  responsible  for  errors
or consequences arising from the use of information contained in these “Just Accepted” manuscripts.Enantioselective Total Synthesis of Hyperforin 
Brian A. Sparling, David C. Moebius, Matthew D. Shair* 
Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States 
 
 Supporting Information Placeholder
ABSTRACT: A modular, 18-step total synthesis of hyper-
forin is described.  The natural product was quickly accessed 
using latent symmetry elements, whereby a group-selective, 
Lewis  acid-catalyzed  epoxide-opening  cascade  cyclization 
was used to furnish the bicyclo[3.3.1]nonane core and set 
two key quaternary stereocenters. 
Hyperforin (1)1,2 was first isolated in 1971 from St. John’s 
Wort (Hypericum perforatum L.) and is now considered to 
be the constituent of the medicinal herb responsible for its 
antidepressant activity.3,4 Hyperforin blocks the reuptake of a 
variety of neurotransmitters through a unique mechanism of 
action,  possibly  by  selectively  activating  TRPC6  (classical 
transient  receptor  potential  protein).5 T R P C 6  a c t i v a t i o n  
leads to a cellular influx of Na+ and Ca2+, diminishing mem-
brane  electrochemical  gradient ( t h u s  indirectly  inhibiting 
neuronal neurotransmitter reuptake) and triggering cell dif-
ferentiation.  As a selective activator of TRPC6, hyperforin is 
a powerful probe of TRPC6 biology, a critical lead for the 
treatment of depression and possibly other human diseases.  
However, the therapeutic potential of hyperforin is severely 
handicapped by its poor water solubility, facile oxidative deg-
radation upon exposure to light and air,6 and potent activa-
tion of pregnane X receptor,7 leading to increased expression 
of many genes involved in xenobiotic metabolism.  Access to 
a wide variety of hyperforin analogs is critical for mitigating 
these  shortcomings  while  maintaining  TRPC6  activation.  
While limited semisynthetic manipulation of isolated hyper-
forin is feasible,8 total synthesis is the only possible means of 
obtaining diverse hyperforin analogs.  
Structurally,  hyperforin  is  one  of  over  200  polycyclic 
polyprenylated  acylphloroglucinol  (PPAP)  natural  prod-
ucts.9 Many PPAPs are characterized by a highly oxidized 
bicyclo[3.3.1]nonane  core  densely  substituted  with  terpe-
noid side chains.  Widespread interest in their bioactivity and 
structural complexity has culminated in the total syntheses of 
several PPAPs.10 While these PPAPs contain a geminal di-
methyl group at the C8 position (hyperforin numbering), 
differential substitution at the hyperforin C8 position ren-
ders these otherwise effective strategies inapplicable toward 
hyperforin  total  synthesis.    Numerous  approaches  toward 
hyperforin11 have only resulted in one total synthesis of ent-
hyperforin, accomplished by the Shibasaki group in 2010.12 
Given the considerable length of this route (51 steps from 
propargyl bromide), we set out to devise a new enantioselec-
tive approach that would not only incorporate elements of 
modularity but also exploit latent symmetry.  A practical total 
synthesis would enable the first full SAR study of hyperforin. 
Scheme 1. (A) Synthesis Strategy for Hyperforin 
(1), (B) Comparison of This Work to Hyperforin 
Biosynthesis. 
 
Our strategy for the construction of hyperforin is shown in 
Scheme  1.    The  synthesis  can  be  deconstructed  into  the 
stepwise fusion of six easily obtainable chemicals (Scheme 
1a).  We postulated that 1 would be accessible from alcohol 
2 through bridgehead acylation at C1 and prenylations at C3 
and C7.  We would access key intermediate 2 from cyclo-
hexadiene 3 via a group-selective, Lewis acid-mediated epox-
ide-opening cyclization.  Cyclohexadiene 3 would be synthe-
sized in two steps through the regioselective coupling of 1,5-
dimethoxy-1,4-cyclohexadiene 4 with prenyl chloride 5 and 
known epoxygeranyl bromide 6.13 
In developing our hyperforin synthesis, we drew inspira-
tion from its proposed biosynthesis14 (Scheme 1b).  In na-
ture, hyperforin is formed from alkylation of a nucleophilic, 
polyketide-derived  acylphoroglucinol  with  geranyl  pyro-
phosphate.  Stereochemical fidelity over the course of this 
coupling in the biosynthesis is governed by enzyme catalysis.  
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Scheme 2. Transition-State Analysis of the Cycli-
zation of 3. 
 
We envisioned utilizing a similar bond disconnection in the 
key cyclization of our synthesis, specifically one involving a 
geraniol-derived fragment. While unable to exploit enzyme-
driven stereoselection, we postulated that an epoxide func-
tionality strategically placed in the geraniol fragment would 
be an effective means of relaying stereochemical information 
to the C1, C5, and C8 carbon centers, when employed in 
concert with a truncated, symmetric cyclohexadiene ring. 
An analysis of the cyclization of 3 is depicted in Scheme 2.  
Owing to the symmetry of compound 3, the quaternary car-
bon at C5 is prostereogenic, and the two methyl enol ethers 
are diastereotopic.  Exposure of 3 to Lewis acid activates the 
epoxide for nucleophilic attack.  While either methyl enol 
ether may engage this activated epoxide, transition state TS-
1 is favored to yield 7 over its diastereomeric transition state 
TS-2, which must adopt a boat-like conformation contain-
ing two severe eclipsing interactions in forming 8.  Addition-
ally, a 6-(enolendo)-tet cyclization should be favored over a 
5-(enolendo)-tet cyclization due to geometric constraints of 
the substrate.15 The contributions of these factors culminate 
in: (1) the formation of the hyperforin bicyclo[3.3.1]nonane 
skeleton; (2) the introduction of stereochemistry at the C5 
quaternary position; and (3) the creation of a stereogenic 
quaternary center at C8.  
Our  synthesis  of  hyperforin  is  depicted  in  Scheme  3.  
Oxymercuration followed by reductive workup of epoxyger-
anyl bromide 6 and subsequent TESCl-mediated silylation 
gave 9.  Over the course of the synthesis, it became apparent 
that formal silanolysis of the olefin present in 6 was indispen-
sible.    Deprotonation  of  cyclohexadiene  4 w i t h  t-BuLi, 
treatment with freshly prepared BaI2,16 and alkylation with 
prenyl chloride 7 yielded diene 11.  In the absence of BaI2, 
non-regioselective prenylation across the pentadienyl anion 
took place.  Coupling of 9 with the anion generated from 
diene 11 and s-BuLi gave cyclization precursor 12.   
Gratifyingly, exposure of 12 to TMSOTf and 2,6-lutidine 
gave the ketal 13 in 79% yield as the only isolated product.  
As  previously  mentioned,  the  stereochemistry  of  two  key 
quaternary centers were established as a result of this trans-
formation: at the previously prostereogenic C5 carbon, and 
at the C8 position.  Aside from the construction of the bicy-
clo[3.3.1]nonane  framework,  the  formation  of  a  cyclic 
methyl ketal was an unexpected yet fortuitous outcome to 
this reaction, safeguarding the C7 carbinol during the subse-
quent allylic oxidation step.  The efficiency of this approach 
was demonstrated by our ability to easily prepare 60 grams of 
13.  
After extensive optimization, allylic oxidation of 13 was 
accomplished using TBHP, PhI(O2CCF3)2, and O2
17 to af-
ford vinylogous ester 14.
18 This was an exceptionally chal-
lenging transformation given the four allylic sites present in 
13 and the steric environment surrounding the desired  
 
Scheme 3. Total Synthesis of Hyperforin (1).a 
 
a Conditions: (a) Hg(OAc)2, Me2CO/H2O; NaOH, 0 ºC; NaBH4, 0 ºC, 91% (b) TESCl, imid, DMF, 97%; (c) t-BuLi, THF, –
78 ºC; BaI2, –78 ºC; 5, –78 to –5 ºC, 85%; (d) 11, s-BuLi, THF, –78 to –30 ºC; 9, –78 to –40 ºC, 85%; (e) TMSOTf, 2,6-lut, 
CH2Cl2, –78 ºC, 79%; (f) PhI(O2CCF3)2, TBHP, Cs2CO3, 4Å MS, EtOAc, O2, –78 to 0 ºC, 44%; (g) BrBMe2, NEt3, CH2Cl2, –
95 ºC; NEt3; sat. aq. NaHCO3, 57%; (h) LiTMP, THF, –78 to 0 ºC, 97%; (i) ClC(S)OC6F5, N-hydroxysuccinimide, pyr, PhMe, 
80 ºC, 82%; (j) allyl–SnBu3, BEt3, PhH, air, 72%; (k) 17, 2-methyl-2-butene, CH2Cl2, 40 ºC, 86%; (l) LiTMP, TMSCl, THF, –
78 to 0 ºC, 90%; (m) LiTMP, THF, –78 to 0 ºC; i-PrC(O)CN, –78 to –30 ºC, 49%; (n) p-TsOH·H2O, PhMe, HOAc, 2-
methyl-2-butene, µwave, 100 ºC, 65%; (o) LDA, THF, –78 ºC; Li(2-Th)CuCN, –78 to –40 ºC; prenyl bromide, –78 to –30 ºC, 
98%; (p) LiCl, DMSO, 120 ºC, 55%. 
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oxidation site.  Hydrolysis of the ketal present in 14 to yield 
alcohol 15 was performed in two steps: treatment of 14 with 
BrBMe2
19 followed by LiTMP-mediated methanol extrusion 
from the intermediate hemiketal.  It was crucial to maintain 
the temperature of the BrBMe2-mediated hydrolysis below –
90 ºC; above this temperature, elimination of the triethylsilyl 
ether was observed.   
After  surveying  a  variety  of  methods  to  install  the  C7 
prenyl group from 15, we pursued a radical Keck allylation 
approach.20 A  r a d i c a l  p r e c u r s o r ,  t h i o n ocarbonate  16,  was 
generated  from  the  reaction  of  alcohol  15 w i t h  
ClC(S)OC6F5.21 Using BEt3/air as an initiator, radical allyla-
tion of 16 with allyl–SnBu3 afforded a product containing a 
C7 allyl group as a single diastereomer.  Employing more 
reactive  radical  precursor  functionality  or  either  photo-
chemical or thermal radical generation conditions gave infe-
rior  results  for  this  coupling  reaction.    An  ensuing  cross-
metathesis with 2-methyl-2-butene catalyzed by Hoveyda–
Grubbs 2nd generation catalyst 1722 afforded 18 containing 
the requisite C7 prenyl moiety.   
After silylation at the C3 position, sequential bridgehead 
deprotonation-acylation using LiTMP and i-PrC(O)CN10n 
yielded ketone 19.  This direct, one-step bridgehead acyla-
tion is noteworthy given that previously reported instances 
of  PPAP  bridgehead  acylation  at  the  C1  position  require 
multiple  steps  involving  a  bridgehead  iodide  intermedi-
ate.10b,d,l  One-pot desilylation and elimination to give 20 was 
accomplished through microwave irradiation of 19 with p-
TsOH·H2O.  The final C3 prenyl group was installed utiliz-
ing  a  precedented  sequence
23 t o  a f f o r d  h y p e r f o r i n  m e t h y l  
ether 21:
24 (1) deprotonation of 20 with LDA, (2) trans-
metalation  with  Li(2-Th)CuCN,25 a n d  ( 3 )  t r a pping  with 
prenyl  bromide.    Finally,  hyperforin  (1)  was  revealed  by 
heating a DMSO solution of 21 with LiCl. 
In summary, we report an enantioselective total synthesis 
of hyperforin.  The synthesis is 18 steps at its longest se-
quence, starting from geraniol.  This approach is also highly 
scalable; to date, we have prepared over 40 mg of hyperforin.  
Latent symmetry elements were utilized to quickly access the 
hyperforin  bicyclo[3.3.1]nonane  core  and  to  set  two  key 
quaternary  stereocenters,  specifically  in  the  conversion  of 
epoxide 12 to ketal 13.  This practical and modular route is 
already being exploited to create diverse hyperforin analogs, 
which we are using to further understand the SAR and un-
derlying mechanisms of hyperforin biological and medicinal 
activity.  Results from these studies will be reported in due 
course. 
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